Microbiotica ’s Post

Catch the replay of our second webinar in the series: 🎥 “Non-clinical case study on our patient-derived xenograft animal model with guest speaker from biotech”. 🔗Click here to access: https://lnkd.in/ePA-bCBE In this session, discover how this innovative approach: ✔️ Served for triple-negative breast cancer providing crucial non-clinical efficacy data ✔️ Anticipates clinical trial outcomes and de-risks efficacy and safety assessments ✔️ Unveils valuable insights into drug mechanisms of action Connect with our speakers: 🔍 Valerie Castellani Lincontang, PhD, Founder & CSO of Oncofactory and Karine Aguera, CDO at StromaCare, previously R&D Project Leader at ERYTECH Pharma. Explore how our model can be provide you with data efficiently for robust preclinical packages. Learn from our collaboration with Erythech, leveraging this model to advance therapies for rare cancers and orphan diseases. Missed our first webinar too? You can still catch up: https://lnkd.in/exnucnPr #webinar #replay #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #ethical #NAM #PDXmodel #PDX #translational #nonclinical #breastcancer

📰 BREAKING: New study published in Nature offers insight into colorectal cancer's development and response to treatment. This study demonstrates: 1) A spectrum of mutational profiles across the colorectum, which reflect aetiological differences. 2) The role of Escherichia colipks+ colibactin in rectal cancers 3) Importance of the SBS93 signature1, which suggests that diet or smoking is a risk factor. 4) Immune-escape driver mutations are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. 5) Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimising patient care. #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #biomarkers #innovation #technology

After examining recent deals in the last year, we’ve highlighted three 2024 M&A deal trends for the #lifesciences industry. Read about each of the below trends here: https://hubs.ly/Q02ky6Sj0 1) Interest in Innovative and First-in-Class Drugs 2) Growth in Oncology & Immunology Spaces 3) Metabolic Disease Drives Interest in Acquisition Activity

🌟 Missed our webinar on patient-derived xenograft animal models? Catch the replay of our second session focusing on the non-clinical application: 🎥 "Non-clinical case study on our patient-derived xenograft animal model with guest speaker from biotech" 🔗 Access the replay here: https://lnkd.in/ePA-bCBE Explore non-clinical efficacy data, insights into drug mechanisms of action, and more with our experts. Don't forget to check out our first webinar: 🎥 "A unique technology platform using an innovative patient-derived xenograft model" 🔗 Access the replay here: https://lnkd.in/exnucnPr #webinar #replay #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #ethical #NAM #PDXmodel 

Missed our webinar on patient-derived xenograft models? Watch the replay of our second session focused on non-clinical applications: 🎥 "Non-clinical case study on our PDX animal model" 🔗 Access it here: https://lnkd.in/e_JJahaJ Discover how ERBC GROUP is innovating oncology drug development with #PDX models and advancing cancer research. #webinar #replay #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #ethical #NAM #PDXmodel

'I should collect as many samples as possible from the patients in my clinical trial.' I hear this a lot from my clients. 'We can store them and use them if something comes up.' I strongly recommend you do not do this. Why? 👉 The likelihood that the samples you have collected are in the correct containers and stored appropriately for the intended assay is low. 👉 This is very cumbersome for the patient who may have to make extra trips to the clinic to provide these samples. Not only that, you could induce anemia or an infection in an already sick individual. 👉 Any samples you collect from the patient must be stored in a way that complies with the Human Tissue Act and similar regulations. This could mean that you have to pay for storage of 1000s of samples for many years after the trial has ended. 👉 Finally - it's just not ethical. You cannot take samples from a patient without having a clear plan of what you will use them for. Be judicious about when you collect your samples. 💡 Pharmacodynamic samples should be collected when you expect to see changes based on preclinical data and assay development information. 💡Collect any surrogate markers of response at times earlier than your first clinical response timepoint but also at the actual clinical response visits. This way you can correlate the clinical response with surrogate markers of response which provides data for future clinical trials with your drug. 💡Collect samples pre-treatment and post-treatment, or at progression. This can be useful for identifying markers of resistance emerging on treatment. ALWAYS make sure you have a baseline reference for any marker you are measuring. This is the most important timepoint. ------- Hi, I'm Josie. I help biopharma create the right biomarker plan for clinical trials. If you'd like to discuss your sample collection strategy or work with me to devise a custom plan for biomarker success, drop me a PM! #clinicaltrials #biopharma #cancer

After examining recent deals in the last year, we’ve highlighted three 2024 M&A deal trends for the #lifesciences industry. Read about each of the below trends here: https://lnkd.in/e5gVnytT 1) Interest in Innovative and First-in-Class Drugs 2) Growth in Oncology & Immunology Spaces 3) Metabolic Disease Drives Interest in Acquisition Activity

Innovative Breakthrough: A New Dawn in Rare Disease Treatment 🌟 In a remarkable leap forward for rare disease therapeutics, a recent Nature publication showcases Vividion Therapeutics, Inc. pioneering advances, lighting the path for future clinical triumphs. Their groundbreaking covalent inhibitor, VVD-133214 (RO7589831), targets the elusive WRN helicase with pinpoint precision, bringing hope to those battling cancers characterized by microsatellite instability 💻📈 Vividion's novel chemoproteomic platform is at the heart of this discovery. The technology scans the proteome to unveil hidden functional pockets within proteins, a game-changer that has historically been dubbed 'undruggable'. This strategic approach has ushered in a new era of drug development, bringing us closer than ever to tailored treatments for complex immune disorders and cancer 💊 But what's truly groundbreaking is that VVD-133214 has already embarked on a clinical voyage, with Phase 1 trials steered by Vividion and its partner Roche. This exemplifies the potential of the chemoproteomics platform, affirming Vividion's position at the vanguard of innovative treatments ✅ #Vividion Therapeutic #Innovation #ClinicalTrials #Oncology #RareDisease #ClinicalResearch #ClinicalTrials #LifeScience #ElixirAssociates #StaffingPartner

FDA accelerates approval of Scemblix (asciminib) for Philadelphia Chromosome-Positive CML   The FDA granted accelerated approval to Scemblix (asciminib, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This milestone offers new hope for patients battling this rare blood cancer. 🔬 Key Safety Insights: • Common adverse reactions (≥20%): Musculoskeletal pain, rash, fatigue, upper respiratory infections, headache, abdominal pain, and diarrhea. • Laboratory abnormalities (≥40%): Decreased lymphocyte, leukocyte, platelet, neutrophil counts, and corrected calcium levels. The approval signals a major step forward in the treatment of Ph+ CML.  📊 GlobalData analysis from Patent Analytics tool shows the key players with publications related to “Treating various Cancer “.   🔗 Want to dive deeper? Check out GD Pharma Intelligence Center https://lnkd.in/gFsbjBTi Not a registered user? Request Demo here https://lnkd.in/eB3Y_Fa    ⚡ Connect with us today to explore the endless possibilities and propel your business forward! 📧 [email protected] or ☎ explore more at our contact page: https://lnkd.in/gSiqRwYh   #FDAApproval #CML #CancerTreatment #Scemblix #PhCML #Oncology #HealthcareInnovation

🚀𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗶𝗻 𝗰𝗼𝗺𝗯𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝗻𝗱 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀🌟 Explore our new molecules in stock: the nanoparticle Paclitaxel (Abraxane®) and the mAb Lebrikizum (Ebglyss®)! Paclitaxel, a potent chemotherapy medication, disrupts the growth of cancer cells by stabilizing microtubules, crucial structures for cell division. On the other hand, lebrikizumab is a monoclonal antibody designed to target interleukin-13 (IL-13), a protein involved in allergic and inflammatory responses. Both licensed molecules represent innovative approaches in combating cancer and inflammatory diseases, offering hope for improved patient outcomes. 🌟 Get the therapeutic Paclitaxel and Lebrikizumab as lab consumables from the original drugs in our online shop (Link in the comments). Discover global access, reliable sourcing, and research benefits! 🌐💼 #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery